To study the link between ␤-amyloid (A␤) and neuroinflammation, we examined the levels of complement as a function of age and extent of A␤ deposition in Down Syndrome (DS) brain. C1q, the first component of the complement cascade, was visualized using immunohistochemistry in the frontal, entorhinal cortex, and hippocampus of 12 DS ranging from 31 to 69 years of age. C1q was consistently associated with thioflavine-S positive A␤ plaques in DS brain and increased with more extensive age-dependent A␤ deposition. In contrast, little or no C1q labeling was associated with diffuse or thioflavine-S negative A␤ deposits. Neurons in the hippocampus and entorhinal cortex, but less frequently in frontal cortex, were C1q positive in DS cases with sufficient neuropathology to have a diagnosis of Alzheimer's disease. C1q-positive neurons were associated with activated microglia. These results provide evidence for A␤-mediated inflammatory factors contributing to the rapid accumulation of neuropathology in DS brain.
INTRODUCTION
Alzheimer's disease (AD) is associated with a progressive loss of cognitive function that is linked to neurodegeneration. The diagnosis of AD is confirmed upon autopsy by the presence of distinctive pathology, including neuronal loss, neurofibrillary tangles and senile plaques (SP) (Mirra et al., 1991) . The major component of SP are extracellular deposits of a 40 -43 amino acid peptide called ␤-amyloid (A␤), which is formed by the cleavage of amyloid precursor protein (APP) (Kang et al., 1987; Selkoe et al., 1994 Selkoe et al., , 1996 Yankner et al., 1996) . In AD, SP are associated with reactive microglia, astrocytes (Carpenter et al., 1993; Maat-Schieman et al., 1994; Potter et al., 1992) and proteins of the complement system (Eikelenboom et al., 1982; Lue et al., 1996) . These features of SP suggest that inflammation is initiated or exacerbated by activation of the complement system and may contribute to the generation of neuropathology (El Khoury et al., 1998; Pasinetti et al., 1996) . Additional support for a role of neuroinflammation in AD pathogenesis is provided by the results of clinical studies demonstrating that anti-inflammatory drugs slow the progression of dementia associated with AD (McGeer et al., 1992 (McGeer et al., , 1996 Stewart et al., 1997) . Recent experimental evidence also confirms that transgenic mice overexpressing human mutant APP fed ibuprofen accumulate significantly less A␤ (Lim et al., 2000) .
We are investigating the hypothesis that A␤ initiates and propagates an inflammatory cascade by activating the complement pathway (CЈ), which is a powerful effector mechanism of the immune system. Fibrillar forms of A␤ can bind and activate C1, the first component of the classical CЈ pathway (Jiang et al., 1994; Rogers et al., 1992; Webster et al., 1997) . The proposed cycle of progressive A␤ deposition followed by CЈ activation would convert a normally acute injury re-
